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Abstract
Psychiatric symptoms are subjective by nature and tend to overlap between different disorders. The modelling of a neuropsychiatric disorder therefore faces 
challenges because of missing knowledge of the fundamental pathophysiology and a lack of accurate diagnostics. Animal models are used to test hypotheses of 
aetiology and to represent the human condition as close as possible to increase our understanding of the disease and to evaluate new targets for drug discovery. 
In this review, genetic and neurodevelopmental animal models of schizophrenia are discussed with respect to behavioural and neurophysiological findings 
and their association with the clinical condition. Only specific animal models of schizophrenia may ultimately lead to novel diagnostic approaches and drug 
discovery. We argue that molecular biomarkers are important to improve animal to human translation since behavioural readouts lack the necessary specificity 
and reliability to assess human psychiatric symptoms.
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Resumo
Sintomas psiquiátricos são subjetivos por natureza e tendem a se sobrepor entre diferentes desordens. Sendo assim, a criação de modelos de uma desordem 
neuropsiquiátrica encontra desafios pela falta de conhecimento dos fundamentos da fisiopatologia e diagnósticos precisos. Modelos animais são usados para 
testar hipóteses de etiologia e para representar a condição humana tão próximo quanto possível para aumentar nosso entendimento da doença e avaliar novos 
alvos para a descoberta de drogas. Nesta revisão, modelos animais genéticos e de neurodesenvolvimento de esquizofrenia são discutidos com respeito a achados 
comportamentais e neurofisiológicos e sua associação com a condição clínica. Somente modelos animais específicos de esquizofrenia podem, em último caso, 
levar a novas abordagens diagnósticas e descoberta de drogas. Argumentamos que biomarcadores moleculares são importantes para aumentar a tradução de 
animais a humanos, já que faltam a especificidade e a fidelidade necessárias às leituras comportamentais para avaliar sintomas psiquiátricos humanos.
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Introduction
According to a prediction of the World Health Organization 
(WHO) neuropsychiatric disorders including schizophrenia, 
depression, bipolar disorder and dementia, will be the greatest 
factor contributing to disease-adjusted life years by the year 20301. 
Epidemiological studies have calculated a lifetime morbidity risk 
for schizophrenia of approximately 1%2. Fundamental research 
into the psychopathology of this disorder and drug development 
during recent years has yielded few answers and more questions. 
One of the major reasons for this lack of progress appears to result 
from the diversity of psychiatric disorders, which often overlap in 
subjectively evaluated symptoms.
Clinical research calls for animal models as a necessary first step 
towards a deeper understanding of psychopathology and to provide 
tools for successful drug discovery. However, current models are only 
able to mimic certain psychiatric symptoms and it is questionable 
if we will ever be able to mirror and evaluate a multifaceted disor-
der such as schizophrenia using animal models. To this end, three 
categories are now assessed for animal models: construct, face and 
predictive validity3.
Construct validity
The degree to which animal models embody and conform to etio-
logical aspects of the disease is termed the construct validity. One 
difficulty with the study of schizophrenia is that we cannot simply 
knock out one risk gene in order to generate symptoms. This is 
because schizophrenia, like most neuropsychiatric disorders, it is 
a multi-locus and multi-factorial disorder. Also, the precipitating 
environmental factors are either unknown or cause a range of 
psychiatric syndromes. This lack of certainty impedes creation of 
animal models with features specific for one psychiatric disorder 
with high construct validity.
Face validity
Face validity is the extent to which animal models reflect the main 
features or symptoms associated with a psychiatric disorder. This has 
most commonly been assessed using behavioural testing. A major 
barrier to development of animal models with high face validity is 
that the primary symptoms of schizophrenia, such as hallucinations, 
delusions, speech abnormalities and inappropriate behaviour, are 
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impossible to model in other species. Nonetheless, several beha-
vioural paradigms have been developed that have some relevance to 
schizophrenia, including hyperlocomotion, social interaction deficits, 
effects on prepulse inhibition (PPI), and intra- and extra-dimensional 
(ID/ED) shifting. The controversial association of hyperlocomotion 
with schizophrenia positive symptoms is based on its post-pubertal 
onset and exacerbation with N-methyl-D-aspartate (NMDA) re-
ceptor antagonists, indicating subcortical dopamine excess4. Social 
interaction deficits are associated with the negative symptom of social 
withdrawal in patients which has been shown to have predictive 
power for the development of schizophrenia in children5-7. 
The Measurement and Treatment Research to Improve Cogni-
tion in Schizophrenia (MATRICS) identified seven domains of 
cognitive dysfunctions in schizophrenia patients including specific 
tests for measurement of these: working memory, verbal memory, 
visual learning, attention/vigilance, abstract reasoning, social cog-
nition and speed of processing8-10. Unlike the changing intensity of 
psychosis, cognitive symptoms tend to accumulate and treatment 
of these has been found to be a better predictor of therapeutic ef-
ficiency and patient outcome than treatment of positive or negative 
symptoms11. Learning and memory tasks are translatable to rodents 
and numerous behavioural paradigms are available. Sensorimotor 
gating deficits are considered endophenotypes of schizophrenia, 
belonging to the category of cognitive impairments. Such deficits are 
related to the inability of schizophrenia patients to ignore irrelevant 
stimuli, and are believed to mirror the positive symptoms causing 
learning deficits and cognitive fragmentation in schizophrenia12-14. 
Human gating defects include reduced P50 auditory evoked potential 
suppression and inhibition of the startle reflex (both measurements 
of PPI), and abnormal smooth eye pursuit, which may reflect fun-
damental causes for the clinical expression of schizophrenia15,16. An 
advantage of such tests is the homology between the human and 
the animal test conditions17. More recently, a rodent analogue of the 
Wisconsin card sorting test (attentional set shifting task) has been 
developed18. Performance in this task measures prefrontal function 
and is impaired in schizophrenia patients. 
Although all of these behavioural hallmarks have translational 
features, they are not likely to be disease-specific19-21. Furthermore, 
all existing animal models represent only distinct features of the 
disease. Considering the complexity of the disorder, it remains 
questionable whether we will achieve creation of an ideal model. 
Therefore, there is an urgent need for identification of translatable 
molecular markers in order to increase confidence in the validity of 
available animal models.
Predictive validity
The utility of a model in the prediction of drug efficacy in the cli-
nic is termed the predictive validity. Assessment of this aspect is 
compromised by our limited knowledge of drug effects. Since the 
first antipsychotic drugs were discovered serendipitously based on 
dopamine receptor blockade, all new drugs have been developed 
in models chosen for their predictive validity as dopamine antago-
nists. However, recent studies have demonstrated the influence of 
antipsychotics on multiple neurotransmitter systems and signalling 
cascades, and progress has been made in moving model development 
away from dopamine pathways.
Aim of this review
This review focuses on relevant behavioural and neurophysiological 
findings in currently used animal models of schizophrenia from 
the perspective of translational neuropsychiatry. Our goal is not 
to list all models but to focus on differential etiological theories of 
schizophrenia and on the models which target these pathways. Fol-
lowing the assumptions of the Research Domain Criteria (RDoC) 
project launched by the NIMH, clinical neuroscience research will 
yield biomarkers to extend the view on psychiatric symptoms and 
improve patient management22. We believe that the correlation of 
schizophrenic patients and psychiatric animal models will result in 
a greater insight in psychopathology and provide the research tools 
essential for novel drug discovery strategies.
Reciprocity of research: finding the “right” aetiology
Many different views on the aetiology of schizophrenia have emerged 
and it is now believed that the pathogenesis results from an interac-
tion of genetic and environmental risk factors3. The neuropathologi-
cal features of the disorder include dysregulation of neurotransmitter 
systems (primarily dopamine and glutamate)23,24, hypofrontality25 
and hippocampal synaptic deficits26. All of these have been followed 
by construction of relevant animal models resulting in a range of 
findings. The aetiological validity of an animal model can only be 
considered as a measurement of the precision of our knowledge of 
human pathogenesis27,28. In spite of the great diversity of aetiological 
findings in schizophrenia research, some aspects have been more 
reproducible in epidemiological studies. This includes genetic heri-
tability and vulnerability during neurodevelopment which form the 
main focus of this review (Figure 1)29-31.
Gift of our ancestors: genes
Genetically modified rodents have become important research mo-
dels in medical sciences in recent years. Modern molecular methods 
allow for targeted gene approaches and can help in discovering the 
neurobiological effects of genes and their interplay on behaviour. 
Genome-Wide Association Studies (GWAS) have facilitated identi-
fication of risk factors including single nucleotide polymorphisms, 
copy number variations and structural or allelic variants, and these 
can be mirrored in animal models. The heritability of schizophrenia 
has been estimated to be around 73% to 90%, based on twin studies 
and currently around 30 risk alleles have been identified32-34. Among 
the polymorphism- and chromosomal-based schizophrenia mouse 
models are the phenotypically-well characterized disrupted in schi-
zophrenia 1 (DISC1), neuregulin 1 (NRG1), proline dehydrogenase 
(PRODH) and 22q11 mutants35. Further models are represented by 
dysbindin (DTNBP1) and reelin (RELN) knock-outs36,37. As with 
all genetic models, the resulting experimental findings should be 
considered with care since schizophrenia appears to be an oligoge-
netic disease with multiple small risk genes accumulating to a give 
a particular phenotype38-40.
DISC1
DISC1 was first discovered due to its co-segregation with psychia-
tric disorders in a Scottish family and it has been found to be an 
important vulnerability factor for schizophrenia and other mental 
disorders in diverse populations41,42. DISC1 has been shown to 
play an essential role in pre- and post-natal neurodevelopment, 
particularly in synaptogenesis, synaptic plasticity and neuronal 
migration43. The commonly used 129S6 Sv/Ev mouse strain has 
been shown to carry a 25bp deletion in exon 6 of this gene, which 
may result in a working memory deficit42. Disorganization and 
impaired plasticity of neurons may be the cause of the cogniti-
ve deficits found in DISC1 mice26. The N-ethyl-N-nitrosourea 
(ENU)-induced Disc1 missense mutation, L100P, produced schi-
zophrenia-like behavioural impairments in PPI, latent inhibition 
and hyperlocomotion which could be blocked by administration 
of typical and atypical antipsychotics44. Working memory deficits 
were also reported for a mouse model of complete DISC1 dele-
tion45. The Q31L missense mutation resulted in the generation 
of mice with deficits in working memory and diminished social 
interaction, and this could be blocked with clozapine44. Both mutant 
strains showed reduced volumes of different brain structures38,46,47. 
Consistent with these findings, DISC1 has been shown to be deve-
lopmentally regulated47,48. At the molecular level, reduced DISC1 
binding to the cAMP-specific 3’,5’-cyclic phosphodiesterase 4B 
(PDE4B) has been demonstrated. PDE4B is a phosphodiesterase 
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which has been implicated in animal models with learning and 
memory impairments44,49,50. Polymorphisms of PDE4B have been 
reported to be associated with schizophrenia in human GWAS51. 
Approaches with mutated human DISC1 in mice have resulted in 
reports of hyperlocomotion, diminished reward learning, impair-
ments in social interaction and declarative memory and increased 
aggression52-54. Structural abnormalities in this model have been 
reported such as enlarged ventricles and decreased dendritic 
arborisation, with decreased expression of lissencephaly 1 (LIS1) 
and synaptosomal-associated protein 25 (SNAP-25)53. LIS1, DISC1 
and nuclear distribution protein nudE-like 1 (NDEL1) have been 
shown to be part of a molecular interaction complex relevant in 
neurodevelopment55-58. Morphological changes in DISC1 mice have 
been observed including reduced prefrontal cortex volume and 
impaired growth and dendritic orientation in the dentate gyrus, 
correlating with findings in human schizophrenia studies59-61.
NRG1
NRG1 has been implicated by GWAS as a risk factor of schizophre-
nia62. The roles of NRG1 and its various isoforms include synapto-
genesis, myelination, glia-neuron interactions, glial cell formation, 
NMDA receptor-regulated neuronal migration and glutamatergic 
signalling at a range of neurodevelopmental stages63-65. Behavioural 
abnormalities have been observed in mice lacking one of the NRG1 
isoforms, including reduced fear conditioning and lower locomotor 
activity66,67. Some of these effects have been shown to be reversed by 
administration of atypical antipsychotics68. Behavioural analyses of 
NRG knockout mice have shown decreased sensorimotor gating and 
social interaction, with increased aggression69-72. Molecular analyses 
of the NMDA receptor in NRG1 knockout mice revealed an overall 
decrease and hypophosphorylation which could be reversed by 
clozapine treatment62,73.
22q11
In schizophrenia research, several studies have been performed on the 
chromosomal microdeletion at 22q11.2 (22q11DS), which results in 
velocardiofacial syndrome (VCFS), with palatal abnormalities, heart 
defects, microcephaly and deformation of thymus or parathyroid 
glands. Some of the cognitive abnormalities observed in patients 
with 22q11DS are thought to originate in the prefrontal cortex and 
hippocampus including deficits in attention, working memory, exe-
cutive function and short-term verbal memory74-76. Approximately 
25% of 22q11DS patients suffer from schizophrenia or schizoaf-
Figure 1. Complications in the aetiology and diagnosis of schizophrenia. (Left) Risk factors for developing schizophrenia – arrows indicate interaction be-
tween the different layers of vulnerability, for example epigenetic changes due to experience of trauma. (Right) Selection of possible non-organic psychiatric 
differential diagnoses with ICD-10 codes202 to be considered before the diagnosis of schizophrenia is possible.
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fective disorder77-79. Also, 6% of early onset schizophrenia patients 
have the same microdeletion80,81. Several genes in this chromosomal 
region have been associated with schizophrenia including proline 
dehydrogenase (PRODH), catechol O-methyl transferase (COMT) 
and guanine nucleotide-binding protein subunit beta-like protein 
1 (GNB1L)82-84. The COMT enzyme has been reported to modulate 
degradation of dopamine in the brain and therefore its absence could 
be responsible for working memory deficits75. Mutations of PRODH 
have been shown to produce neurotransmitter abnormalities in 
glutamatergic and dopaminergic pathways of genetically modified 
mice75. Selective deletion of PRODH in mice has been shown to lead 
to deficits in sensorimotor gating, with decreased glutamate, aspartate 
and GABA levels in the frontal cortex85. Proline has been implicated 
in modulation of neurotransmission especially in the glutamatergic 
system, which could lead to the psychotic symptoms observed in 
patients86-88. 22q11DS mouse models present with a loss of glutama-
tergic synapses, decreased spine density, decreased CA1 pyramidal 
neuron complexity and reduced neurogenesis in the subventricular 
zone. The same mice show behavioural abnormalities in PPI, hyper-
locomotion, fear conditioning and working memory89-94. 22q11DS 
is the only confirmed recurrent structural mutation associated with 
schizophrenia identified to date95.
Mutations in neuronal signal transmission pathways
Neurotransmitter deficits have been modelled using genetic methods. 
Higher dopamine concentrations in the synaptic cleft can be simula-
ted by knock-out of the dopamine transporter (DAT). Such mice have 
been classified as models of schizophrenia as they are hyperactive in 
novel environments, express excessive stereotypic behaviour, reduced 
reward learning, deficits in sensorimotor gating, working and decla-
rative memory, and show circadian rhythm impairments96-99. The 
modified neuron-oscillatory properties caused by DAT knock-out 
have also been shown to influence the serotonergic system, possibly 
as compensation for the hyperdopaminergia100,101. The hypothalamic-
pituitary-adrenal axis in these mice is dysregulated, resulting in an-
terior pituitary hypoplasia102, similar to effects seen in schizophrenic 
patients103. Also, approximately 50% lower concentrations of D1 and 
D2 postsynaptic receptor mRNA have been described in the striatum 
of these animals as well as downregulation of preproenkephalin A 
(PENK) and upregulation of dynorphin (PDYN)96,97. Following the 
glutamate hypothesis, a mutant mouse strain has been created with 
a 90% reduction in NMDA receptor 1 (NR1) expression, resulting 
in social and sexual behavioural deficits and similar symptoms to 
the DAT knock out mouse. These include impaired circadian rhy-
thm, memory and gating deficits, diminished reward learning and 
increased locomotion104-107. These symptoms could be reduced with 
haloperidol and clozapine treatment104. Reduced NMDA-signalling 
induced by gene knockdown resulted in impaired habituation of the 
auditory startle response, similar to that induced by phencyclidine 
(PCP) administration, and mimicking the sensory overload believed 
to be experienced by many schizophrenic patients106,108. The observed 
loss of parvalbumin-positive neurons in NMDA deficient mice has 
also been linked with schizophrenia-like symptoms and has been 
reported for hippocampal interneurons21,109,110.
Vulnerability of our youth: neurodevelopment
The existence of an environmental component of schizophrenia was 
demonstrated by the finding that identical twins show a concordance 
of approximately 50%111. The neurodevelopmental character of schi-
zophrenia was postulated based on epidemiological, human post-
mortem tissue and imaging studies112. Neurodevelopmental animal 
models include maternal immune activation, prenatal malnutrition, 
the interruption of neurogenesis by methylazoxymethanol (MAM) 
and the neonatal ibotenic acid lesion of the ventral hippocampus113,114. 
Additional models are represented by the exposure of pregnant 
mice to unpredictable stress, maternal separation or birth compli-
cations115-117. All of these models have revealed behavioural deficits 
associated either with positive, cognitive or negative symptoms of 
schizophrenia, and alterations in the dopaminergic, glutamatergic, 
GABAergic and serotonergic systems118-124.
Maternal immune activation
Maternal immune activation is considered to be an etiological fac-
tor in schizophrenia based on epidemiological studies of influenza 
infection in mothers of schizophrenia patients, and an increased 
incidence of schizophrenia among winter births125-127. This has been 
modelled in rodents by infecting pregnant animals with viruses or by 
administration of the bacterial endotoxin lipopolysaccharide (LPS). 
Sensorimotor gating was reported to be impaired in male and female 
offspring of mothers treated with LPS between gestation day 15 and 
19, but the effects in male mice were more severe128. A reduction 
of glycogen synthase kinase 3 β (GSK3B) mRNA in the prefrontal 
cortex was consistent with the findings of human post-mortem tissue 
analyses128-131. Male offspring of maternal immune activation showed 
an increase in tumour necrosis factor α (TNF) throughout their 
lifespan, as seen in schizophrenia128,132,133. Antipsychotics have been 
shown to reverse the effects of maternal immune activation on the 
behavioural and serum cytokine levels134,135. Maternal infection of 
rodents with influenza virus has led to deficits in social interaction 
and acoustic PPI in the offspring136. Prenatal influenza infection has 
been associated with impaired corticogenesis and cell layer disrup-
tions in the hippocampus, together with altered expression of synaptic 
markers118,137. This is similar to the finding of hippocampal pyramidal 
cell disarray reported in human schizophrenia post-mortem stu-
dies138-140. Because the influenza virus or influenza virus antibodies 
have not been detected in the fetal brain, it has been hypothesized 
that the maternal immune response alone is sufficient to generate 
schizophrenia-like behavioural findings in the offspring136,141-145. At 
the neurotransmitter level, dysfunctions in the dopaminergic and 
glutamatergic system have been reported, especially in the medial 
prefrontal cortex and the nucleus accumbens in offspring from 
mothers subjected to immune challenge123.
Maternal protein malnutrition
Prenatal malnutrition has been shown to be a risk factor for schi-
zophrenia146-148. Maternal malnutrition in rats was followed by 
attention and gating deficits on the behavioural level but only in fe-
male offspring149. This was associated with increased 3H-Haloperidol 
binding in the striatum, as found in studies of male rats following 
maternal malnutrition121,149, although there are conflicting reports 
of this150. Increased 3H-MK-801 binding in the striatum and hippo-
campus was described in the maternal malnutrition model and may 
reflect a NMDA receptor hypofunction and subsequent up-regulation 
as postulated by the glutamate hypothesis of schizophrenia121,151. Me-
mory deficits in this model were described in terms of susceptibility to 
interference and extinction, further supporting theories of prefrontal 
and hippocampal psychopathology152. Offspring of malnourished 
mothers showed reduced social interaction and higher aggressive 
behaviour, similar to findings in malnourished children153,154. Increa-
sed concentrations of noradrenaline and dopamine were reported 
following malnutrition, resulting most likely from tyrosine hydroxy-
lase hyperactivity and this correlated with reduced overall brain and 
hippocampus size155. Additionally GABAA receptors (GABAAR) have 
been reported to be decreased in the hippocampus of adult offspring 
subjected to maternal malnutrition119.
Interruption of neurogenesis
Administration of the mitotoxin methylazoxymethanol acetate 
(MAM) to rat dams on embryonic day 17 (E17) interferes with 
development of schizophrenia-relevant brain regions in the 
offspring114,120,156,157. Several mechanisms of action have been proposed 
to explain the actions of MAM-E17 treatment, including a decrease in 
the levels of reelin and the 67 kDa form of glutamic acid decarboxylase 
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(GAD67), as reported in schizophrenic patients, or by methylation of 
genes critical for neuronal development and plasticity158-160. Neuroa-
natomical findings reported in parallel for the MAM-E17 model and 
schizophrenic patients include morphological changes in the prefron-
tal cortex, parahippocampal cortex and hippocampus, reduced size 
of the medial dorsal thalamus and increased neuron packaging in the 
frontal lobe114,161-165. A decrease in whole brain volume of MAM-E17 
rats was mainly focussed on the prefrontal cortex, hippocampus and 
nucleus accumbens120. Cellular disarray in the CA1 region of hippo-
campus has also been described and is thought to be analogous to 
hippocampal disarray seen in schizophrenia patients120,166. Recently, 
we carried out a proteomic and metabonomic investigation which 
showed that MAM-E17 rats have primarily deficits in hippocampal 
glutamatergic neurotransmission, as seen in some schizophrenia 
patients167. Most importantly, these results were consistent with our 
finding of functional deficits in glutamatergic neurotransmission, as 
identified using electrophysiological recordings. At the behavioural le-
vel, dysfunctions in sensorimotor gating in MAM-E17 rats have been 
described in line with findings in schizophrenic patients, implicating 
frontal dysfunctions and dopaminergic input to the striatum114,168. So-
cial interaction deficits have been described to occur before and after 
puberty in MAM-E17 rats, although hypermotor activity and deficits 
in spatial working memory and PPI occurred only after puberty169. 
Furthermore, the offspring of MAM-E17 rats displayed working 
memory deficits in object recognition, as do schizophrenic patients, 
implicating deficits in the prefrontal cortex120,170, 171. Additional eviden-
ce for prefrontal abnormalities has been reported by impairments in 
latent inhibition120,172-174. Cortical pyramidal neurons from MAM-E7 
offspring failed to reduce their firing frequency as did control neurons 
if dopamine was artificially injected175. This finding has relevance to 
conditional associative learning which has been described as being 
impaired in schizophrenia patients176. 
Neonatal hippocampal lesion
The neonatal hippocampal lesion rat model was developed after 
reports that this region affected mesolimbic dopamine transmission 
and cortical dopamine turnover in schizophrenia113. Ibotenic acid 
was administered on postnatal day 7 to damage the ventral hippo-
campus, which connects to the prefrontal cortex, analogous to the 
human anterior hippocampus. These animals showed hypermotor 
activity and hyper-responsiveness to stress emerging in adulthood 
(day 56). Also, the effect could be blocked by haloperidol treatment113. 
Conversely, sensorimotor gating deficits in this model have been 
shown to be treatable with the atypical antipsychotics clozapine, 
olanzapine and risperidone but not with the typical antipsychotic 
haloperidol177. This may be a useful model for schizophrenia due to 
the post-pubertal emergence of PPI deficits, as seen in the human 
disease, which are thought to result from damage to the prefrontal 
cortex17,178,179. Further behavioural tests have revealed deficits in 
spatial learning and memory, beginning in the juvenile period180. 
Reduced social interaction has been reported in this model prior to 
and after puberty, although this effect does not appear to respond 
to clozapine treatment181. This may be relevant in light of studies 
showing that prodromal individuals demonstrate difficulties in 
establishing friendships and emotional bonding5,182-184. Molecular 
studies have shown increased AMPA receptor (GRIA3) levels in 
the prefrontal cortex of ventral hippocampal lesion rats, which may 
be the cause of striatal dopaminergic hyperactivation185,186. Finally, 
studies on neuronal circuitry in the prefrontal cortex in this model 
have shown abnormal synaptic responses to excitatory input, which 
is of interest given the deficit in inhibitory interneurons found in 
the prefrontal cortex of schizophrenic post-mortem tissue124,187,188.
Translation of animals to humans and back again
Currently, animal behaviours which parallel specific characteristics 
of psychiatric disorders such as schizophrenia are used in drug 
development as early indicators of potential treatment efficacy. Ho-
wever, the use of behavioural readouts is limited in disease specificity 
and this has been regarded as one of the major drawbacks of these 
approaches189. In particular, the assessment of similarities of animal 
behaviour and patient characteristics can be subjective, leading to 
problems of bias and irreproducibility. Due to such difficulties, the 
disease relevance of many animal models for schizophrenia remains 
dubious.
One means of overcoming these problems is the demonstration 
that data accumulated from relevant animal model studies are re-
presentative of human schizophrenia190. A simple approach would be 
to consider the molecular changes in blood serum or plasma which 
have been associated consistently with schizophrenia and attempt to 
correlate these findings with those in animal models of schizophrenia 
which target particular aspects of the disease. For example similar 
changes have been identified between specific animal models and 
human schizophrenia in the case of molecules such as adrenocor-
ticotrophic hormone191, corticosteroid hormones192, brain-derived 
neurotrophic factor192, interleukin 2193, interleukin 6193, kynurenic 
acid194 and glutamate195. Such parallels in molecular changes may lead 
to the establishment of construct validity of a given animal model.
The efficient use of reverse translational research seems likely 
to guide the way for characterization of disease mechanisms and 
identifying novel drug targets. This is critical as the future clinical 
need in the field of neuropsychiatry calls for identification of class- or 
even drug-specific biomarkers matched with novel therapeutic ap-
proaches. This could be done by statistical analyses of the complex 
data generated in proteomic approaches in animals and humans 
alike. Once discovered and matched, new biomarkers could be used 
to evaluate the comparability of the animal model and the disease 
status in humans and treatment effects could be validated more 
efficiently than with behavioural tests. The goal of these molecular 
profiling approaches is the identification of cross species signatures 
of a given human disease. In this way, the best animal models for 
developing and testing novel therapeutic strategies can be identified.
Conclusions
This review summarized behavioural findings and key features on 
the morphological, cellular and molecular level in commonly used 
animal models of schizophrenia generated with genetic and neu-
rodevelopmental approaches. It should be no surprise that none of 
the listed animal models has been established as the “best” for use in 
drug discovery, because none are able to mimic the human disease 
state in all measurable variables. Psychiatric patients present with 
multiple subtle symptoms, which cannot be measured reproducibly 
by existing techniques. Therefore, it is not likely that such symptoms 
can be recapitulated in animal models. In fact, several observations 
have been made which negatively impact on face validity such as the 
appearance of higher locomotor activity in some models which has 
no distinct counterpart in schizophrenic patients196. The need for 
this paradigm change is reflected in the ongoing debate about the 
introduction of the Diagnostic and Statistical Manual V (DSM-V). 
Current psychiatric practice includes the assessment of patient 
symptoms using clinically approved interviews which are not based 
on the underlying pathophysiology. It should be no surprise that 
clinical syndromes based on subjective symptoms are a source of 
misdiagnosis and therefore mistreatments. 
To address the problems of combining the next generation of 
diagnostic rules with the findings of modern neuroscience, the 
National Institute of Mental Health has initiated the establishment 
of a classification guide of psychiatric patients for research proposes 
and for a better incorporation of modern scientific knowledge on the 
field of neuropsychiatry22. The RDoC provides a multidimensional 
view of “constructs” like behaviourally evaluated cognitive deficits 
and molecular neurobiological alterations. The major advantage of 
this approach is the freedom of diagnoses for certain syndromes, 
circumventing the problem of disease categories. RDoC represents 
a dimensional system ranging from normality to abnormality. With 
the exploitation of physiological measures and molecular biomarkers, 
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this will enable a better integration of animal models in pre-clinical 
research and enhance their potential to generate value from bench 
to bedside. Recently new approaches have emerged to integrate 
new parameters into this process, such as molecular changes in 
easy accessible peripheral samples (for example saliva) and electro-
cardiographic measurements for early detection and diagnosis of 
stress-related psychopathogenesis in humans and for verification of 
animal models of psychiatric disorders197.
This review has focussed on the genetic and neurodevelop-
mental models of schizophrenia. Despite the fact that these were 
created to model schizophrenia, they represent great variability 
in their behavioural findings and it is difficult to evaluate them 
with respect to given symptoms. In the case of human psychiatric 
disorders, symptoms often overlap between different psychiatric 
disorders and psychiatrists are faced with a diversity of possible 
differential diagnoses (Figure 1). Dysfunctions of PPI, for example, 
have been reported in many neuropsychiatric and even in some 
non-neuropsychiatric disorders198.
Molecular findings have been used to show similarities between 
humans and rodents supporting the view that behaviour alterations 
are linked to molecular changes190,199. Given the reported pool of 
findings it seems unlikely that a difference in any single molecule 
would be enough to assign a given animal model to a distinct psy-
chiatric disorder. This is in line with biomarker findings which have 
focussed on altered patterns rather than changes of single proteins200. 
For example it has been shown that a combination of 51 serum 
biomarkers can be used in humans to help with the diagnosis of 
schizophrenia201. Further molecular analyses of molecular patterns 
in psychiatric animal models need to be correlated with human stud-
ies to identify signatures associated with specific alterations on the 
genetic level or with the consequences of environmental insults. The 
use of biomarkers specific for different symptoms could help in new 
pharmacological approaches. For example current typical and atypi-
cal drugs fail mainly in targeting the negative and cognitive symptoms 
of schizophrenia11,182,202. The study of genetic and neurodevelopmental 
models could enable us to better identify risk biomarkers and help 
to initiate research programmes for discovery of novel treatments 
which target the fundamental pathogenesis instead of the current 
approach of symptom reduction. The relationship between genetic 
and environmental impact will probably remain the focus of current 
neuropsychiatric research over the next decade and the increased use 
of disease-relevant animal models could lead to new insights. The 
additional application of the RDoC system into modern approaches 
with psychiatric animal models could enhance the exchange between 
the preclinical and clinical stage and help to overcome the current 
stagnation in translational research.
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